You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
|
|---|---|
| Published in |
Journal of Translational Medicine, October 2013
|
| DOI | 10.1186/1479-5876-11-259 |
| Pubmed ID | |
| Authors |
John J Nemunaitis, Karen A Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao, Rajat Bannerji |
| Abstract |
Dinaciclib, a small-molecule, cyclin-dependent kinase inhibitor, inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. We conducted an open-label, dose-escalation study to determine the safety, tolerability, and bioactivity of dinaciclib in adults with advanced malignancies. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Egypt | 1 | 1% |
| Unknown | 83 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 18% |
| Student > Bachelor | 11 | 13% |
| Researcher | 10 | 12% |
| Student > Master | 7 | 8% |
| Other | 6 | 7% |
| Other | 9 | 11% |
| Unknown | 27 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 13 | 15% |
| Agricultural and Biological Sciences | 13 | 15% |
| Medicine and Dentistry | 13 | 15% |
| Chemistry | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Other | 10 | 12% |
| Unknown | 26 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2020.
All research outputs
#5,240,498
of 25,374,647 outputs
Outputs from Journal of Translational Medicine
#914
of 4,635 outputs
Outputs of similar age
#45,517
of 223,621 outputs
Outputs of similar age from Journal of Translational Medicine
#14
of 93 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,635 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,621 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.